2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0217
    Benzoylaconine 466-24-0 99.92%
    Benzoylaconine (Benzoylaconitine) is an orally active monoester alkaloid found in the traditional Chinese medicine Aconitum carmichaelii. Benzoylaconine is an ACE2 agonist (EC50: 1.5 μM) with antihypertensive and anti-heart failure effects. Benzoylaconine inhibits TLR-induced MAPK and NF-κB pathways to exert anti-inflammatory effects. Benzoylaconine upregulates the protein levels of P-gp, MRP2, and has anti-tumor effects.
    Benzoylaconine
  • HY-112490
    Atorvastatin calcium hydrate 344423-98-9 99.64%
    Atorvastatin calcium salt trihydrate is a drug belonging to the statin class of drugs used to lower blood cholesterol levels. Atorvastatin calcium salt trihydrate has unique chemical properties that make it an effective tool in controlling high levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the body, reducing the risk of heart attack and stroke. Atorvastatin calcium salt trihydrate works by inhibiting HMG-CoA reductase, the enzyme responsible for producing cholesterol in the liver.
    Atorvastatin calcium hydrate
  • HY-N0908
    Ginsenoside Rg5 186763-78-0 ≥99.0%
    Ginsenoside Rg5 is the main component of Red ginseng and IGF-1R agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of IGF-1 to IGF-1R (IC50 about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.
    Ginsenoside Rg5
  • HY-14181
    Cinaciguat 329773-35-5 99.73%
    Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.
    Cinaciguat
  • HY-100447
    TM5275 sodium 1103926-82-4 98.97%
    TM5275 sodium is a plasminogen activator inhibitor (PAI-1) with an IC50 of 6.95 μM.
    TM5275 sodium
  • HY-100828
    BGP-15 66611-37-8 ≥98.0%
    BGP-15 is a PARP inhibitor, with an IC50 and a Ki of 120 and 57 μM, respectively.
    BGP-15
  • HY-14299
    Indacaterol 312753-06-3 99.98%
    Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research.
    Indacaterol
  • HY-A0016
    Dronedarone 141626-36-0 99.93%
    Dronedarone (SR 33589), a derivative of amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone is a substrate for and a moderate inhibitor of CYP3A4.
    Dronedarone
  • HY-12724A
    Guanabenz hydrochloride 23113-43-1 99.94%
    Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure.
    Guanabenz hydrochloride
  • HY-B1203A
    Fludrocortisone acetate 514-36-3 99.37%
    Fludrocortisone acetate (9α-Fludrocortisone acetate) is an orally active synthetic mineralocorticoid. Fludrocortisone acetate can effectively control sodium retention. Fludrocortisone acetate is used in studies of cardiac injury, adrenal insufficiency and orthostatic hypotension.
    Fludrocortisone acetate
  • HY-P99227
    Caplacizumab 915810-67-2 ≥99.0%
    Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the binding of vWF with platelet glycoprotein (GP) Ibα. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP).
    Caplacizumab
  • HY-34350
    2-(Aminomethyl)phenol 932-30-9 ≥98.0%
    2-(Aminomethyl)phenol (2-Hydroxybenzylamine), a selective dicarbonyl scavenger, is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). 2-(Aminomethyl)phenol can be used in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias.
    2-(Aminomethyl)phenol
  • HY-A0168
    Regadenoson 313348-27-5 99.59%
    Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS.
    Regadenoson
  • HY-B1189
    Meglutol 503-49-1 ≥98.0%
    Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases.
    Meglutol
  • HY-D1458
    Peroxyfluor 1 817170-66-4
    Peroxyfluor 1 is a cell-permeable probe for H2O2. Peroxyfluor 1 represents a first-generation, green-fluorescent probe.
    Peroxyfluor 1
  • HY-N0368
    Linalool 78-70-6 ≥98.0%
    Linalool is a natural monoterpene which is a competitive NMDA receptor antagonist. Linalool is orally active and crosses the blood-brain barrier. Linalool has anticancer, antibacterial, anti-inflammatory, neuroprotective, anxiolytic, antidepressant, anti-stress, cardioprotective, hepatoprotective, nephroprotective and pulmonary protective activities.
    Linalool
  • HY-N0447
    8-Gingerol 23513-08-8 99.82%
    8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC50 value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.
    8-Gingerol
  • HY-101016
    17-ODYA 34450-18-5 ≥98.0%
    17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes. 17-ODYA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    17-ODYA
  • HY-103200
    SR59230A hydrochloride 1135278-41-9 99.81%
    SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively.
    SR59230A hydrochloride
  • HY-106369
    HMR 1556 223749-46-0 ≥99.0%
    HMR 1556, a chromanol derivative, is a potent IKs blocker with IC50s of 10.5 nM and 34 nM in canine and guinea pig left ventricular myocytes, respectively.
    HMR 1556
Cat. No. Product Name / Synonyms Application Reactivity